FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.
about
FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
FDA Approval Summary: Lenalido ...... ly Diagnosed Multiple Myeloma.
@en
FDA Approval Summary: Lenalido ...... ly Diagnosed Multiple Myeloma.
@nl
type
label
FDA Approval Summary: Lenalido ...... ly Diagnosed Multiple Myeloma.
@en
FDA Approval Summary: Lenalido ...... ly Diagnosed Multiple Myeloma.
@nl
prefLabel
FDA Approval Summary: Lenalido ...... ly Diagnosed Multiple Myeloma.
@en
FDA Approval Summary: Lenalido ...... ly Diagnosed Multiple Myeloma.
@nl
P2093
P2860
P1433
P1476
FDA Approval Summary: Lenalido ...... ly Diagnosed Multiple Myeloma.
@en
P2093
Amy E McKee
Andrew Dmytrijuk
Ann T Farrell
Elizabeth Dianne Pulte
Kirsten B Goldberg
Richard Pazdur
P2860
P356
10.1634/THEONCOLOGIST.2017-0440
P577
2018-02-07T00:00:00Z